<https://helda.helsinki.fi>

Clinical and Genetic Characterization of 153 Patients with Persistent or Transient Congenital Hyperinsulinism

Männistö, Jonna M. E.

2020-04

Männistö , J M E , Maria , M , Raivo , J , Kuulasmaa , T , Otonkoski , T , Huopio , H & Laakso , M 2020 , ' Clinical and Genetic Characterization of 153 Patients with Persistent or Transient Congenital Hyperinsulinism ' , Journal of Clinical Endocrinology and Metabolism , vol. 105 , no. 4 , 271 . <https://doi.org/10.1210/clinem/dgz271>

<http://hdl.handle.net/10138/327963>

<https://doi.org/10.1210/clinem/dgz271>

unspecified

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

1 **Clinical and genetic characterization of 153 patients with persistent or transient congenital**
2 **hyperinsulinism**

3 Jonna M. E. Männistö¹, Maleeha Maria², Joose Raivo², Teemu Kuulasmaa³, Timo Otonkoski⁴, Hanna
4 Huopio^{5*}, Markku Laakso^{5*}

5 ¹ Department of Pediatrics, University of Eastern Finland, and Kuopio University Hospital, Kuopio, Finland

6 ² Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland

7 ³ Institute of Clinical Medicine, Internal Medicine, and Institute of Biomedicine, Bioinformatics
8 Center, University of Eastern Finland, Kuopio, Finland

9 ⁴ Children's Hospital, University of Helsinki, and Helsinki University Hospital, Helsinki, Finland

10 ⁵ Department of Pediatrics, Kuopio University Hospital, Kuopio, Finland

11 ⁶ Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, and Kuopio University
12 Hospital Kuopio, Finland

13 * Equal contribution.

14 **Funding:** This work was funded by the the Academy of Finland (to ML), the Foundation for Pediatric
15 Research (to JM and HH, grant numbers 140025, 160041, and 170069), the Finnish Cultural Foundation,
16 North Savo Regional Fund (to JM), VTR grant from the Kuopio University Hospital (to JM), the Päivikki
17 and Sakari Sohlberg Foundation (to JM).

18 **Keywords:** Hyperinsulinemic hypoglycemia, genetics, genotype-phenotype correlation

19 **Disclosure summary:** The authors have nothing to disclose.

20 **Address all correspondence and requests for reprints to:** Jonna Männistö, MD, Department of
21 Pediatrics, Kuopio University Hospital, P.O. Box 100, FI-70029 Kuopio University Hospital, Kuopio,
22 Finland. E-mail: jonna.mannisto@kuh.fi.

23 Abstract

24 **Context** Major advances have been made in the genetics and classification of congenital hyperinsulinism
25 (CHI).

26 **Objective** To examine the genetics and clinical characteristics of patients with persistent and transient
27 CHI.

28 **Design** A cross-sectional study with the register data and targeted sequencing of 104 genes affecting
29 glucose metabolism.

30 **Patients** Genetic and phenotypic data were collected from 153 patients with persistent (n = 95) and
31 transient (n = 58) CHI diagnosed between 1972 and 2015. Of these, 86 patients with persistent and 58
32 with transient CHI participated in the analysis of selected 104 genes affecting glucose metabolism,
33 including ten CHI-associated genes, and nine patients with persistent CHI were included with their
34 previously confirmed genetic diagnosis.

35 **Main outcome measures** Targeted next-generation sequencing results and genotype-phenotype
36 associations.

37 **Results** Five novel and 21 previously reported pathogenic or likely pathogenic variants in *ABCC8*,
38 *KCNJ11*, *GLUD1*, *GCK*, *HNF4A* and *SLC16A1* genes were found in 68% (n = 65) and 0% of the patients
39 with persistent and transient CHI, respectively. K_{ATP} channel mutations explained 82% of the mutation
40 positive cases.

41 **Conclusions** The genetic variants found in this nationwide CHI cohort are in agreement with previous
42 studies, mutations in the K_{ATP} channel genes being the major causes of the disease. Pathogenic CHI-
43 associated variants were not identified in patients who were both diazoxide-responsive and able to
44 discontinue medication within the first four months. Therefore, our results support the notion that genetic
45 testing should be focused on patients with inadequate response or prolonged need for medication.

46 Introduction

47 Congenital hyperinsulinism (CHI) is a rare genetically, clinically and histologically heterogeneous
 48 disorder in which pancreatic beta cells secrete increased amounts of insulin resulting in hypoglycemia
 49 (1,2). CHI comprises persistent (P-CHI) and transient (T-CHI) cases, and it can be also related to certain
 50 syndromes (2).

51 Previously published studies show that 38-79% of P-CHI cases are associated with a pathogenic
 52 or likely pathogenic CHI-associated variant, and currently, 14 genes have reported to associate with CHI
 53 (*ABCC8*, *KCNJ11*, *GCK*, *GLUD1*, *HNF4A*, *HNF1A*, *HADH*, *SLC16A1*, *UCP2*, *HK1*, *PGM1*, *PMM2*,
 54 *FOXA2*, and *CACNAD1*) (3-7). Variants in the K_{ATP} channel genes *ABCC8* and *KCNJ11* account for the
 55 most cases of P-CHI for which a genetic cause has been identified. P-CHI is further classified into four
 56 distinct subgroups, 1) recessive diazoxide-responsive, 2) dominant diazoxide-responsive, 3) dominant
 57 diazoxide-unresponsive, and 4) focal CHI caused by uniparental disomy, resulting from a somatic loss
 58 of maternal allele in chromosome region 11p15 (1,8). We have previously shown that the two founder
 59 mutations in the K_{ATP} channel gene, *ABCC8*/p.Val187Asp and *ABCC8*/p.Glu1506Lys, explain 58% of
 60 all P-CHI cases (9,10). A recessive p.Val187Asp variant results in a more severe, typically diazoxide-
 61 unresponsive disease, and a dominant p.Glu1506Lys variant results in a relatively mild form of CHI
 62 (9,10).

63 T-CHI is typically associated with maternal gestational diabetes or perinatal stress, and is usually
 64 resolved within weeks after birth, but it may also be severe and last up to few months and hence resemble
 65 the clinical course of P-CHI (11,12).

66 Clinical symptoms of hypoglycemia appear usually during the neonatal period or early infancy. These
 67 include generalized (e.g. hypothermia, hypotonia, or poor feeding) or neuroglycopenic symptoms (e.g.
 68 lethargy, seizures), especially in the most severe cases (1,2). Clinical manifestations of CHI can have a
 69 wide spectrum, and therefore, the identification of the persistent form of the disease from other causes
 70 of neonatal hypoglycemia may be challenging. Genetic testing has been suggested for patients who do
 71 not respond, who need a high dose, or have a prolonged need for diazoxide (13). The genetic diagnosis

may have an important role when planning the treatment, especially in the patients with paternal K_{ATP} channel gene variant and focal form of CHI, which can be cured by localized resection of pancreas.

In the present study, we investigated the genetic etiology and the genotype-phenotype associations in a nationwide cohort of patients with CHI.

Material and Methods

Study participants

The study cohort was recruited from the national CHI registry of 238 patients in Finland (P-CHI, $n = 106$; T-CHI, $n = 132$). The patients were identified by a diagnosis-based search for 'other' or 'unspecified hypoglycemia', including hyperinsulinism, (Disease classification ICD-8 from 1969, ICD-9 from 1987, and ICD-10 from 1996) of the hospital registries from all five Finnish University Hospitals, and 14 central hospitals. These patients are likely to represent all affected individuals diagnosed in Finland during that time, although the possibility of undiagnosed cases especially in the 1970-80s cannot be excluded.

The inclusion criteria for the registry and the current study were the diagnosis of CHI based on a combination of diagnostic findings of prolonged or recurrent hypoglycemia and signs of inappropriate insulin secretion, i.e. detectable serum insulin level and/or low free fatty acids during non-ketotic hypoglycemia. The increased need for intravenous glucose (>8 mg/kg/min) was used as supportive criteria in neonatal cases. Only patients who needed medication for hyperinsulinism (diazoxide or octreotide, which were used as alternatives for each other) were included. The definition of hypoglycemia was based on the recommendations of the Pediatric Endocrine Society: ≤ 2.8 mmol/l (≤ 50 mg/dL) in the first 48 hours of life, and ≤ 3.3 mmol/l (≤ 60 mg/dL) thereafter (14).

Targeted sequencing of selected 104 genes affecting glucose metabolism, including ten CHI-associated genes (15), was offered to all registry patients. Some of the 94 other genes have rare variants which could potentially cause hypoglycemia and increased insulin levels, and over time lead to hyperglycemia. Of the whole registry, 86 patients with P-CHI and 58 patients with T-CHI were willing to participate. Additionally, nine P-CHI patients whose genetic diagnosis was already available in the

98 medical records were included. Hence, altogether 153 patients (P-CHI, n = 95; T-CHI, n = 58) diagnosed
 99 between the years 1972 and 2015 were included in this study. Participation rates were 90% (95 of 106)
 100 in P-CHI and 44% (58 of 132) in T-CHI group. One parent of five patients and both parents of one
 101 patient were of non-Finnish origin, but all other participants (96%) were of Finnish origin.

102 For our study protocol, we classified the patients retrospectively into the T-CHI group, when
 103 hyperinsulinism was detected during the neonatal period (< 28 days after birth), there was no need to
 104 increase the dosing of medication (mg/kg/d) after achieving remission, the medication was successfully
 105 discontinued within the first four months, i.e. there was no evidence of recurrent hypoglycemia in blood
 106 glucose measurements by finger-prick tests or continuous glucose monitoring during or after medication.
 107 All other patients with a late onset, long duration of medication or surgical treatment were classified as
 108 having P-CHI.

109 Severe symptoms at onset referred to seizure or coma and mild symptoms to any other
 110 hypoglycemia symptoms. Diazoxide-responsiveness was defined clinically, when an asymptomatic
 111 child had normal blood glucose levels and did not need intravenous glucose infusion.

112 ***Targeted next-generation sequencing***

113 The gene panel included 10 CHI-associated genes published by the time of the genetic analysis and
 114 additionally selected 94 genes affecting glucose metabolism (15). Genomic DNA was extracted from
 115 blood samples (P-CHI, n = 86; T-CHI, n = 58) by automated QIAcube System and QIAamp DNA Blood
 116 Mini Kits (Qiagen Inc, CA, USA). HaloPlex Target Enrichment System (Agilent Technologies, Santa
 117 Clara, CA, USA) was used to capture regions of interest for next generation sequencing. Online design
 118 tool SureDesign (<https://earray.chem.agilent.com/suredesign/>) was used for capture probe design. Target
 119 regions consisted of exons, UTRs and 10bp flanking regions of 104 glucose metabolism associated genes
 120 from the RefSeq database (GRCh37/hg19), including ten CHI-associated genes (*ABCC8*, Online
 121 Mendelian Inheritance in Man[®], OMIM: 600509; *KCNJ11*, OMIM: 600937; *GCK*, OMIM: 138079;
 122 *GLUD1*, OMIM: 138130; *HNF4A*, OMIM: 600281; *HNF1A*, OMIM: 142410; *HADH*, OMIM: 601609;
 123 *SLC16A1*, OMIM: 600682; *UCP2*, OMIM: 601693; and *HK1*, OMIM: 142600) (15). The total length

124 of the target regions was 484566 kbp and involved 1418 regions. Design yielded 18838 amplicons
 125 covering 481.37 kbp of target regions. Library preparation was performed using HaloPlex Target
 126 Enrichment Kit by following manufacturer's instructions. Paired-end sequencing (2x300 bp) was
 127 performed on MiSeq instrument (Illumina, San Diego, CA, USA) using the MiSeq Reagent Kits v3 (600
 128 cycles).

129 ***Data analysis and variant calling***

130 In-house developed analysis pipeline was used for the analysis of raw fastq files generated by the MiSeq-
 131 sequencer. Cutadapt (<https://code.google.com/p/cutadapt/>) software was used for Illumina sequencing
 132 adapter removal and read trimming. Reads shorter than 20bp were abandoned. Remaining reads were
 133 mapped to human reference genome hg19 using BWA-MEM algorithm ([http://bio-](http://bio-bwa.sourceforge.net/)
 134 [bwa.sourceforge.net/](http://bio-bwa.sourceforge.net/)). Variant calling (SNVs and indels) was performed using four different variant
 135 callers: GATK HaplotypeCaller (<https://www.broadinstitute.org/gatk/>), SAMTools mpileup
 136 (<http://samtools.sourceforge.net/>), Atlas2 (<http://sourceforge.net/projects/atlas2/>), Platypus
 137 (<https://bio.tools/platypus>). All called variants were annotated using SnpEff
 138 (<http://snpeff.sourceforge.net/>), ANNOVAR (<http://annovar.openbioinformatics.org/>), and multiple
 139 different public databases (e.g. 1000 Genomes, dbSNP, ClinVar and gnomAD). Variants had to meet
 140 the following criteria to be included in the downstream analysis: located within the exonic or splicing
 141 regions, have high or moderate effect on gene function, and have unknown or variant allele frequency
 142 below 2% in the 1000 genomes variant database. The alignments at variant positions were visually
 143 inspected using the Integrative Genomics Viewer (<https://www.broadinstitute.org/igv/>).

144 *In silico analyses of genetic variants.* The pathogenicity of the variants was assessed according to the
 145 guidelines of the American College of Medical Genetics and Genomics and the Association of Molecular
 146 Pathology, ACMG (16). We classified the variants into five different groups (pathogenic, likely
 147 pathogenic, uncertain significance, likely benign, benign) based on evidence population frequency of
 148 the variant, computational data, functional data, and segregation data. We used the following *in silico*
 149 programs to evaluate the pathogenicity of each variant, Sorting Intolerant From Tolerant (SIFT) (17),

150 Polymorphism Phenotyping2 (PolyPhen2), HumVar module (18), Mutation taster (19), and MutPred
 151 (20). *In silico* analysis of intronic, synonymous, and canonical splice-site variants on splicing was done
 152 by Alamut visual version 2.9, which is a commercial software from Interactive Biosoftware
 153 (alamut.interactive-biosoftware.com). Additionally, we searched for functional evidence for
 154 pathogenicity based from previously published studies. Only pathogenic or likely pathogenic variants
 155 are reported.

156 *Variant validation.* All pathogenic or likely pathogenic variants were validated by Sanger sequencing
 157 using BigDye Terminator v1.1 Cycle Sequencing Kit and analyzed by 3500XL Genetic Analyzer
 158 (Thermo Fisher Scientific Inc, MA, USA) with 3500 data collection software 2. We performed sequence
 159 analysis using Chromas Lite 2.1.1 © 1998-2013, program from Technelysium Pty Ltd.

160 *Ethical considerations.* The study was approved by the Ethics Committee of the Northern Savo Hospital
 161 District and was conducted in accordance with the Helsinki Declaration. All patients (and/or their
 162 parents) who participated in the genetic analysis, gave their written consent. The nine patients with an
 163 available genetic diagnosis and without genetic analysis in this study were included based on the
 164 permission for registry study.

165 **Results**

166 *Clinical characteristics.* Clinical characteristics of the patients are presented in Table 1 and online
 167 repository (15). In P-CHI (n = 95) and T-CHI groups (n = 58), 56% and 64% of the subjects were males,
 168 the median age at the onset of hypoglycemia was 1 day (range, 1 d to 8 yrs) and 1 day (1 to 2 d), and the
 169 median age at the start of medication was 17 days (1 d to 8 yrs) and 7 days (1 to 27 d), respectively.
 170 Altogether, 64% and 100% of the patients with P-CHI and T-CHI responded to diazoxide treatment. Of
 171 the 32 operated patients with P-CHI, 13 had partial resection for a focal or multifocal CHI and 19 near-
 172 total or total pancreatectomy.

173 **Persistent CHI**

174 *Genetic variants.* In total, five novel and 21 previously reported (4,9,10,21-35) pathogenic or likely
 175 pathogenic variants were identified in 65 patients with P-CHI from 55 families (Table 2, (15)). None of
 176 the 58 unrelated patients with T-CHI carried a pathogenic or likely pathogenic variant.

177 The distribution of pathogenic or likely pathogenic gene variants of patients with P-CHI is presented
 178 in Figure 1. As a whole, these variants in six CHI-associated genes, *ABCC8*, *KCNJ11*, *GLUD1*,
 179 *SLC16A1*, *GCK*, and *HNF4A*, explained the genetic etiology in 68% (n = 65) of the patients. K_{ATP}
 180 variants were the most common causes of CHI (82%, n = 53).

181 *ABCC8 variants.* Altogether, 17 different *ABCC8* variants were identified, including four novel variants,
 182 explaining 75% (n = 49) of the mutation positive cases (Table 2, Figure 1, (15)). The previously
 183 characterized two Finnish founder mutations (*ABCC8*/p.Val187Asp (9) and *ABCC8*/p.Glu1506Lys (10))
 184 explained 58% (n = 38) of the genetic etiology of P-CHI patients. The autosomal recessive
 185 *ABCC8*/p.Val187Asp (9) variant was found in 24 patients from 23 families, explaining the genetic
 186 etiology in 37% of the mutation positive patients. Five patients were homozygous and four compound
 187 heterozygous for *ABCC8*/p.Val187Asp. They tended to be born preterm (67%) and were large for
 188 gestational age (67%). All had neonatal-onset within two days after the birth and all were diazoxide-
 189 unresponsive. This subgroup and especially the patients with the homozygous variant tended to have the
 190 highest plasma insulin levels at diagnosis (Table 1, (15)). Fifteen patients were heterozygous for
 191 *ABCC8*/p.Val187Asp. All these patients were diazoxide-unresponsive. Sixty-seven percent had neonatal
 192 onset, but only 13% were born large for gestational age.

193 The autosomal dominant founder mutation *ABCC8*/p.Glu1506Lys (10) was detected in 14 patients
 194 from six families, explaining the genetic etiology in 22% of the cases. Of these, 93% had a neonatal
 195 onset, 50% were born large for gestational age, and 93% were diazoxide-responsive (Table 1).

196 Four novel *ABCC8* variants were identified (Table 2, (15)). One patient carried a novel pathogenic
 197 frameshift variant *ABCC8*/p.Lys1094Glufs*19 and a pathogenic *ABCC8*/p.Arg526Cys variant. The
 198 patient was born large for gestational age, responded well to diazoxide, and had a milder phenotype than
 199 other patients with compound heterozygous variants. The other novel heterozygous variants were

200 *ABCC8*/p.Glu1516Ala and *ABCC8*/p.Gln1458Lys (*de novo*). The carriers of these variants were large
 201 for gestational age, had neonatal-onset, and were responsive to diazoxide. In the latter patient, ¹⁸F-
 202 DOPA-PET scan referred to a multifocal disease.

203 Ten patients were heterozygous and one compound heterozygous for other *ABCC8* variants than the
 204 previously mentioned founder mutations p.Val187Asp or p.Glu1506Lys, and four of these *ABCC8*
 205 variants were novel (Table 2, (15)). These patients tended to be large for gestational age (64%) and have
 206 neonatal onset (91%) (Table 1). None had severe symptoms at onset and 64% were diazoxide-
 207 responsive. Six of the 11 patients had paternal inheritance referring to focal CHI. Focal lesion was
 208 confirmed in surgery in four of them and two other were successfully treated with diazoxide.

209 *KCNJ11* variants. Four patients from three families carried a pathogenic or likely pathogenic *KCNJ11*
 210 variant (Table 2, (15)). All had neonatal onset and 50% were born large for gestational age (Table 1).
 211 One of the patients was compound heterozygous for *KCNJ11*/p.Lys67Asn and a promoter variant
 212 (substitution C to T at -54 bases proximal of the translation initiation site) that has been previously
 213 predicted to lead to a novel start codon and reduced number of K_{ATP} channels (27). This patient had a
 214 severe phenotype requiring near-total pancreatectomy.

215 *GLUD1* variants. Two previously reported heterozygous *GLUD1* variants were identified in six patients
 216 from three families (Table 2, (15)). These associated with an onset after the neonatal period (> 28 days
 217 after birth) (83%), severe symptoms at onset (50%), and diazoxide-responsiveness (100%) (Table 1).
 218 Diazoxide was started for two children after a positive test result of the variant found in the parent.
 219 Plasma ammonium levels were elevated at diagnosis (range from 95 to 318 umol/l).

220 *GCK* variants. Two patients carried pathogenic *GCK* variants. One patient carried a novel pathogenic
 221 activating *GCK*/p.Thr65Ala variant (Table 2, (15)). The patient had normal birth size and remained
 222 asymptomatic until the age of 8 years. This patient was treated with diazoxide but the treatment could
 223 be discontinued after normoglycemia was achieved with dietary treatment. An activating
 224 *GCK*/p.Tyr213Cys variant (*de novo*) in another patient caused an extremely severe and drug-resistant
 225 form of CHI, as previously reported (33).

226 *HNF4A* variants. A previously reported likely pathogenic variant *HNF4A*/p.Arg331His, which has been
 227 associated with MODY (35), was found in one patient having a mild neonatal-onset CHI, which
 228 responded well to diazoxide treatment (Table 2, (15)).

229 *SLC16A1* variants. Two previously reported heterozygous *SLC16A1* variants,
 230 *SLC16A1*/p.Asp15Argfs*34 and a *SLC16A1* promoter variant (25 bp insertion at the position c.-391_-
 231 390) were found in three patients (Table 2, (15)). The phenotype associating to these variants has been
 232 previously described (36,37). In our cohort, the other patient with the promoter variant did not have clear
 233 clinical signs of exercise-induced hyperinsulinism (EIHI).

234 **Transient CHI**

235 None of the patients with T-CHI carried a disease-causing CHI variant. In this group, 45% were born
 236 preterm and only 14% were large for gestational age. The median birth weight was -1.2 SDS and none
 237 had severe symptoms at onset (Table 1). The median plasma insulin levels at diagnosis tended to be
 238 lower compared with the patients with P-CHI (16 vs. 25 mU/l; ranges 2-116 and 2-531 mU/l). One or
 239 more risk factors for hyperinsulinism of a newborn (maternal gestational diabetes or the use of beta
 240 blockers, small for gestational age, prematurity < 37 gestational weeks, or perinatal stress) was identified
 241 in 66% (n = 38) of the patients with T-CHI. The corresponding proportion in the P-CHI group was 53%
 242 (n = 50).

243 **Syndrome-related CHI**

244 Three participants had a syndrome previously associated with hyperinsulinism (Beckwith-Wiedemann
 245 syndrome (38), Turner mosaicism (39)). No CHI-associated genetic variants were identified in these
 246 patients (15).

247 **Mutation negative patients with persistent CHI**

248 Altogether, 32% (n = 30) of the subjects with P-CHI did not have a pathogenic or likely pathogenic
 249 variant (Figure 1). Of these, 53% had a neonatal-onset of the disease. Eighty-six percent were diazoxide-
 250 responsive. Two patients underwent pancreatectomy, and two had focal resection of pancreas. ¹⁸F-

251 DOPA-PET scan referred to a focal CHI in two patients but they were successfully treated with
 252 medication.

253 **Discussion**

254 We investigated the genetics of CHI and the genotype-phenotype relationships in a nationwide cohort
 255 consisting almost entirely of Finnish patients with P-CHI or T-CHI. CHI-associated pathogenic or likely
 256 pathogenic variants were identified in 68% and 0% of the patients with P-CHI and T-CHI, respectively,
 257 including five novel variants.

258 Previous large studies have reported CHI-associated variants in 45% (from 2 to 8 genes
 259 sequenced) (3,5) and 79% (9 genes sequenced, syndromic CHI excluded) (4). Other smaller studies have
 260 reported pathogenic variants in 38-66% of the patients (6 to 9 genes sequenced) (6,7,40,41). Our results
 261 are in agreement with these reports. Furthermore, variants in the K_{ATP} channel genes explained 82% of
 262 the variants in our study, as has also been reported in previous studies (6,7,40,41).

263 Homozygosity or compound heterozygosity for the recessive K_{ATP} channel gene variants were
 264 associated with the most severe phenotypes, whereas variants in other than K_{ATP} channel genes were
 265 associated with diazoxide-responsivity, except for an inactivating *GCK* variant. The patients with a
 266 *GLUD1* variant showed elevated ammonium levels. Of the 20 paternally inherited heterozygous K_{ATP}
 267 gene variants, 65% were associated with focal or multifocal forms of CHI which was successfully treated
 268 with partial resection (15). Three patients carried a pathogenic variant in *SLC16A1* gene, and two of
 269 them presented classical exercise-induced hyperinsulinism, but the clinical signs of EIHI were lacking
 270 in one patient most likely due to his young age.

271 Interestingly, seven patients with heterozygous missense K_{ATP} variants and one with compound
 272 heterozygous *ABCC8* variant were treated with diazoxide. The heterozygous variants may be dominant,
 273 as previously demonstrated by functional analysis in all monoallelic diazoxide-responsive K_{ATP} variants
 274 of a large cohort (4). In addition, a similar compound heterozygous case has been previously
 275 demonstrated to be diazoxide-responsive in functional analysis (42). Moreover, it is also possible that
 276 cell adaptation and gene regulatory factors may contribute to the severity of CHI in all these eight

277 patients (13,42). Several patients in our study carried a heterozygous, paternally inherited *ABCC8* variant
278 and were diazoxide-unresponsive, but did not have a focal CHI. This may be explained by another yet
279 unidentified variant, unidentified focal disease, dominant variant (in others than patients with
280 p.Val187Asp), or contributing epigenetic factors (43,44). Our findings are in agreement with previous
281 studies showing the heterogeneity of CHI (1,4,13,42,43).

282 To our knowledge, our study is the first one performing extensive genetic analyses of patients with
283 T-CHI. These patients responded well to diazoxide and the treatment could be discontinued within the
284 first four months, the maximal diazoxide dose tended to be lower than in most patients with P-CHI, and
285 none of these patients carried a pathogenic variant. Our findings are in agreement with a recently
286 provided algorithm suggesting that genetic testing is appropriate only for the patients who are diazoxide-
287 unresponsive or need a high diazoxide dose, and in patients who continue on medication (regardless of
288 the dose) after 6 months (13).

289 Targeted next-generation sequencing of selected 104 genes associated with glucose metabolism (15)
290 did not reveal any novel candidate genes for CHI in our study. Gene panels including previously known
291 disease-causing genes are important in clinical diagnostics, but identification of new causative genes is
292 only possible through exome or whole genome sequencing.

293 Our study has some limitations. First, we did not perform functional studies of the identified novel
294 variants. However, we used a wide range of *in silico* methods to predict the pathogenicity of all detected
295 variants. Second, we applied targeted next-generation sequencing, which does not detect larger
296 deletions/insertions or variants in non-coding region. This may underestimate the number of patients
297 with pathogenic or likely pathogenic variants. Third, it is possible that some of the patients who were
298 not identified with a pathogenic or likely pathogenic variant may have actually had T-CHI, since exact
299 classification criteria are missing to differentiate T-CHI and P-CHI. Although the national diagnosis
300 registries are mandatory and reliable, it cannot be excluded that some patients especially with a milder
301 phenotype in the 1970-80's have been un- or misdiagnosed. Finally, four currently known CHI-
302 associated genes were not included in our panel for the reason that these genes were mostly published

303 after we had completed our genetic analysis. However, our gene panel was the largest compared to the
304 previous studies.

305 In conclusion, the results of our study demonstrated that K_{ATP} channel genes were the major
306 identified cause of CHI, and that the genotype-phenotype associations were consistent in several specific
307 CHI subgroups. Pathogenic CHI-associated variants were not identified in patients who were both
308 responsive for drug treatment and able to discontinue medication within the first four months, and
309 therefore our results support the notion that genetic testing should be primarily done on patients with
310 inadequate response or prolonged need for medical therapy.

311 **Acknowledgements**

312 -

313 **Data availability**

314 Restrictions apply to the availability of data generated or analyzed during this study to preserve patient
315 confidentiality or because they were used under license. The corresponding author will on request
316 detail the restrictions and any conditions under which access to some data may be provided.

317 **Table legends**

318 Table 1. Clinical characteristics of the patients with persistent CHI (n = 95) and transient CHI group (n
319 = 58) according to the genetic variants.

320 Table 2. Pathogenic or likely pathogenic variants of the patients with CHI.

321 **Figure legend**

322 Figure 1. The frequencies of pathogenic or likely pathogenic variants in all patients with P-CHI (A)
323 and the distribution of these variants (B).

324

325 **References**

- 326 [1] Stanley C A. Perspective on the Genetics and Diagnosis of Congenital Hyperinsulinism Disorders.
327 J Clin Endocrinol Metab 2016; 101: 815-26.
- 328 [2] Galcheva S, Al-Khawaga S, Hussain K. Diagnosis and management of hyperinsulinaemic
329 hypoglycaemia. Best Pract Res Clin Endocrinol Metab 2018; 32: 551-73.
- 330 [3] Kapoor R R, Flanagan S E, Arya V B, Shield J P, Ellard S, Hussain K. Clinical and molecular
331 characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrinol 2013; 168: 557-64.
- 332 [4] Snider K E, Becker S, Boyajian L, et al. Genotype and phenotype correlations in 417 children with
333 congenital hyperinsulinism. J Clin Endocrinol Metab 2013; 98: E355-63.
- 334 [5] Mohnike K, Wieland I, Barthlen W, et al. Clinical and genetic evaluation of patients with KATP
335 channel mutations from the German registry for congenital hyperinsulinism. Horm Res Paediatr 2014;
336 81: 156-68.
- 337 [6] Rozenkova K, Malikova J, Nessa A, et al. High Incidence of Heterozygous ABCC8 and HNF1A
338 Mutations in Czech Patients With Congenital Hyperinsulinism. J Clin Endocrinol Metab 2015; 100:
339 E1540-9.
- 340 [7] Gong C, Huang S, Su C, et al. Congenital hyperinsulinism in Chinese patients: 5-yr treatment
341 outcome of 95 clinical cases with genetic analysis of 55 cases. Pediatr Diabetes 2016; 17: 227-34.
- 342 [8] Glaser B, Ryan F, Donath M, et al. Hyperinsulinism caused by paternal-specific inheritance of a
343 recessive mutation in the sulfonylurea-receptor gene. Diabetes 1999; 48: 1652-7.
- 344 [9] Otonkoski T, Ammala C, Huopio H, et al. A point mutation inactivating the sulfonylurea receptor
345 causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes
346 1999; 48: 408-15.
- 347 [10] Huopio H, Reimann F, Ashfield R, et al. Dominantly inherited hyperinsulinism caused by a
348 mutation in the sulfonylurea receptor type 1. J Clin Invest 2000; 106: 897-906.
- 349 [11] de Lonlay-Debeney P, Poggi-Travert F, Fournet J C, et al. Clinical features of 52 neonates with
350 hyperinsulinism. N Engl J Med 1999; 340: 1169-75.
- 351 [12] Stanley C A, Rozance P J, Thornton P S, et al. Re-evaluating "transitional neonatal
352 hypoglycemia": mechanism and implications for management. J Pediatr 2015; 166: 1520,5.e1.
- 353 [13] Banerjee I, Salomon-Estebanez M, Shah P, Nicholson J, Cosgrove K E, Dunne M J. Therapies
354 and outcomes of congenital hyperinsulinism-induced hypoglycaemia. Diabet Med 2019; 36: 9-21.
- 355 [14] Thornton P S, Stanley C A, De Leon D D, et al. Recommendations from the Pediatric Endocrine
356 Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and
357 Children. J Pediatr 2015; 167: 238-45.
- 358 [15] Männistö J M E, Maria M, Raivo J, et al. Data from: Clinical and genetic characterization of 153
359 patients with persistent or transient congenital hyperinsulinism. Figshare. Deposited 29 October 2019.
360 <https://doi.org/10.6084/m9.figshare.8977496>.

- 361 [16] Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence
362 variants: a joint consensus recommendation of the American College of Medical Genetics and
363 Genomics and the Association for Molecular Pathology. *Genet Med* 2015; 17: 405-24.
- 364 [17] Ng P C, Henikoff S. Predicting deleterious amino acid substitutions. *Genome Res* 2001; 11: 863-
365 74.
- 366 [18] Adzhubei I, Jordan D M, Sunyaev S R. Predicting functional effect of human missense mutations
367 using PolyPhen-2. *Curr Protoc Hum Genet* 2013; Chapter 7: Unit7.20.
- 368 [19] Schwarz J M, Cooper D N, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the
369 deep-sequencing age. *Nat Methods* 2014; 11: 361-2.
- 370 [20] Li B, Krishnan V G, Mort M E, et al. Automated inference of molecular mechanisms of disease
371 from amino acid substitutions. *Bioinformatics* 2009; 25: 2744-50.
- 372 [21] Tornovsky S, Crane A, Cosgrove K E, et al. Hyperinsulinism of infancy: novel ABCC8 and
373 KCNJ11 mutations and evidence for additional locus heterogeneity. *J Clin Endocrinol Metab* 2004; 89:
374 6224-34.
- 375 [22] Arya V B, Guemes M, Nessa A, et al. Clinical and histological heterogeneity of congenital
376 hyperinsulinism due to paternally inherited heterozygous ABCC8/KCNJ11 mutations. *Eur J*
377 *Endocrinol* 2014; 171: 685-95.
- 378 [23] Stanley C A, Thornton P S, Ganguly A, et al. Preoperative evaluation of infants with focal or
379 diffuse congenital hyperinsulinism by intravenous acute insulin response tests and selective pancreatic
380 arterial calcium stimulation. *J Clin Endocrinol Metab* 2004; 89: 288-96.
- 381 [24] Thomas P M, Cote G J, Wohlk N, et al. Mutations in the sulfonylurea receptor gene in familial
382 persistent hyperinsulinemic hypoglycemia of infancy. *Science* 1995; 268: 426-9.
- 383 [25] Tanizawa Y, Matsuda K, Matsuo M, et al. Genetic analysis of Japanese patients with persistent
384 hyperinsulinemic hypoglycemia of infancy: nucleotide-binding fold-2 mutation impairs cooperative
385 binding of adenine nucleotides to sulfonylurea receptor 1. *Diabetes* 2000; 49: 114-20.
- 386 [26] Flanagan S E, Clauin S, Bellanne-Chantelot C, et al. Update of mutations in the genes encoding
387 the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1
388 (ABCC8) in diabetes mellitus and hyperinsulinism. *Hum Mutat* 2009; 30: 170-80.
- 389 [27] Huopio H, Jaaskelainen J, Komulainen J, et al. Acute insulin response tests for the differential
390 diagnosis of congenital hyperinsulinism. *J Clin Endocrinol Metab* 2002; 87: 4502-7.
- 391 [28] Muzyamba M, Farzaneh T, Behe P, et al. Complex ABCC8 DNA variations in congenital
392 hyperinsulinism: lessons from functional studies. *Clin Endocrinol (Oxf)* 2007; 67: 115-24.
- 393 [29] Sharma N, Crane A, Gonzalez G, Bryan J, Aguilar-Bryan L. Familial hyperinsulinism and
394 pancreatic beta-cell ATP-sensitive potassium channels. *Kidney Int* 2000; 57: 803-8.
- 395 [30] Flanagan S E, Kapoor R R, Banerjee I, et al. Dominantly acting ABCC8 mutations in patients
396 with medically unresponsive hyperinsulinaemic hypoglycaemia. *Clin Genet* 2011; 79: 582-7.

- 397 [31] Santer R, Kinner M, Passarge M, et al. Novel missense mutations outside the allosteric domain of
398 glutamate dehydrogenase are prevalent in European patients with the congenital hyperinsulinism-
399 hyperammonemia syndrome. *Hum Genet* 2001; 108: 66-71.
- 400 [32] Stanley C A, Lieu Y K, Hsu B Y, et al. Hyperinsulinism and hyperammonemia in infants with
401 regulatory mutations of the glutamate dehydrogenase gene. *N Engl J Med* 1998; 338: 1352-7.
- 402 [33] Cuesta-Munoz A L, Huopio H, Otonkoski T, et al. Severe persistent hyperinsulinemic
403 hypoglycemia due to a de novo glucokinase mutation. *Diabetes* 2004; 53: 2164-8.
- 404 [34] Otonkoski T, Jiao H, Kaminen-Ahola N, et al. Physical exercise-induced hypoglycemia caused by
405 failed silencing of monocarboxylate transporter 1 in pancreatic beta cells. *Am J Hum Genet* 2007; 81:
406 467-74.
- 407 [35] Wang X, Wang T, Yu M, et al. Screening of HNF1A and HNF4A mutation and clinical
408 phenotype analysis in a large cohort of Chinese patients with maturity-onset diabetes of the young.
409 *Acta Diabetol* 2019; 56: 281-8.
- 410 [36] Otonkoski T, Kaminen N, Ustinov J, et al. Physical exercise-induced hyperinsulinemic
411 hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate-induced insulin
412 release. *Diabetes* 2003; 52: 199-204.
- 413 [37] van Hasselt P M, Ferdinandusse S, Monroe G R, et al. Monocarboxylate transporter 1 deficiency
414 and ketone utilization. *N Engl J Med* 2014; 371: 1900-7.
- 415 [38] Munns C F, Batch J A. Hyperinsulinism and Beckwith-Wiedemann syndrome. *Arch Dis Child*
416 *Fetal Neonatal Ed* 2001; 84: F67-9.
- 417 [39] Gibson C E, Boodhansingh K E, Li C, et al. Congenital Hyperinsulinism in Infants with Turner
418 Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency. *Horm Res*
419 *Paediatr* 2018; 89: 413-22.
- 420 [40] Fan Z C, Ni J W, Yang L, et al. Uncovering the molecular pathogenesis of congenital
421 hyperinsulinism by panel gene sequencing in 32 Chinese patients. *Mol Genet Genomic Med* 2015; 3:
422 526-36.
- 423 [41] Faletra F, Athanasakis E, Morgan A, et al. Congenital hyperinsulinism: clinical and molecular
424 analysis of a large Italian cohort. *Gene* 2013; 521: 160-5.
- 425 [42] Arya V B, Aziz Q, Nessa A, Tinker A, Hussain K. Congenital hyperinsulinism: clinical and
426 molecular characterisation of compound heterozygous ABCC8 mutation responsive to Diazoxide
427 therapy. *Int J Pediatr Endocrinol* 2014; 2014: 24-9856.
- 428 [43] Bellanne-Chantelot C, Saint-Martin C, Ribeiro M J, et al. ABCC8 and KCNJ11 molecular
429 spectrum of 109 patients with diazoxide-unresponsive congenital hyperinsulinism. *J Med Genet* 2010;
430 47: 752-9.
- 431 [44] Banerjee I, Skae M, Flanagan S E, et al. The contribution of rapid KATP channel gene mutation
432 analysis to the clinical management of children with congenital hyperinsulinism. *Eur J Endocrinol*
433 2011; 164: 733-40.
- 434

Table 1. Clinical characteristics of the patients with persistent CHI (n = 95) and transient CHI group (n = 58) according to the genetic variants.

	Persistent CHI										Transient CHI
	KATP channel variants										Mutation negative
	<i>ABCC8</i> p.V187D (HOM or CH)	<i>ABCC8</i> p.V187D (HET)	<i>ABCC8</i> p.E1506K	<i>ABCC8</i> other (HET or CH)	<i>KCNJ11</i> (HET or CH)	<i>GLUD1</i>	<i>GCK</i>	<i>SLC16A1</i>	<i>HNF4A</i>	Persistent CHI Mutation negative	
<i>n</i>	9	15	14	11	4	6	2	3	1	30	58
Gender M / F (%)	33 / 67	53 / 47	50 / 50	46 / 54	75 / 25	67 / 33	50 / 50	33 / 67	0 / 100	67 / 33	64 / 36
Gestational age, weeks	36 (29-39)	40 (36-42)	38 (33-40)	38 (36-41)	37 (27-40)	39 (37-41)	40 (40-40)	40 (39-41)	39	39 (31-42)	37 (31-41)
Preterm, % (n) ¹	66.7 (6)	13.3 (2)	35.7 (5)	18.2 (2)	50.0 (2)	0.0 (0)	0.0 (0)	0.0 (0)	0.0 (0)	20.0 (6)	44.8 (26)
Birth weight SDS	+2.5 (+0.4-6.6)	+0.5 (-2.4-2.3)	+1.4 (-0.4-4.5)	+2.3 (-0.5-7.2)	+2.4 (+0.7-6.1)	-2.6 (-2.9-0.8)	+1.7 (+1.7-1.7)	-0.4 (-1.6-0.9)	+1.7	+0.4 (-3.3-3.9)	-1.2 (-3.9-4.6)
Large for gestational age, % (n) ²	66.7 (6)	13.3 (2)	50.0 (7)	63.6 (7)	50.0 (2)	0.0 (0)	0.0 (0)	0.0 (0)	0.0 (0)	10.0 (3)	13.8 (8)
Neonatal onset, % (n)	100.0 (7)	66.7 (10)	92.9 (13)	90.9 (10)	100.0 (4)	16.7 (1)	50.0 (1)	0.0 (0)	0.0 (0)	53.3 (16)	NA
Age at detection of hypoglycemia, d	1 (1-2)	1 (1-203)	1 (1-183)	1 (1-1)	1 (1-1)	160 (27-219)	1617 (1-3233)	808 (616-931)	43	42 (1-878)	NA
Severe symptoms at onset, % (n)	33.3 (3)	26.7 (4)	0.0 (0)	0.0 (0)	0.0 (0)	50.0 (3)	50.0 (1)	33.3 (1)	0.0 (0)	33.3 (10)	0.0 (0)
Max iv-glucose rate, mg/kg/min ³	14.5 (10.0-25.9)	11.8 (4.0-21.0)	9.0 (7.4-10.0)	12.9 (8.3-15.8)	16.3 (12.0-20.0)	NA	NA	NA	NA	14.1 (6.2-21.0)	12.7 (5.1-20.0)
Plasma insulin during hypoglycemia, mU/l	57 (25-531)	24 (5-200)	21 (2-140)	21 (12-38)	46 (30-106)	28 (17-80)	25 (25)	74 (16-131)	41	20 (5-60)	16 (2-116)
Diazoxide, max dose, mg/kg/d	11.3 (6.3-34.0)	13.2 (3.8-23.8)	6.4 (3.3-15.6)	14.0 (5.1-21.0)	14.5 (11.4-17.6)	10.0 (6.7-12.0)	NA	6.7 (4.0-12.0)	6.2 (NA)	12.5 (4.4-22.0)	9.5 (2.3-20.1)
Diazoxide-responsive, % (n) ⁴	0.0 (0)	0.0 (0)	92.9 (13)	63.6 (7)	0.0 (0)	100.0 (6)	50.0 (1)	100.0 (3)	100.0 (1)	86.2 (25)	100.0 (54)
Surgery, % (n)	100.0 (9)	80.0 (12)	7.1 (1)	36.4 (4)	25.0 (1)	0.0 (0)	50.0 (1)	0.0 (0)	0.0 (0)	13.3 (4)	NA

Categorical variables represented as percentage (%) and number (n) of the patients. Continuous variables represented as median (range) values. HOM, homozygous; HET, heterozygous; CH, compound heterozygous; P/LP, pathogenic/likely pathogenic; ¹ Born before 37 gestational weeks; ² Birth weight SDS > 2.0; ³ In neonates; ⁴ When used.

Table 2. Pathogenic or likely pathogenic variants of the patients with congenital hyperinsulinism.

Gene	Transcript	Allele	Protein	<i>In silico</i> analyses	Carriers (<i>n</i>)	Ref.
<i>ABCC8</i>	NM_000352.4	c.560T>A	p.(Val187Asp)	P	24	(9)
		c.1576C>T [‡]	p.(Arg526Cys)	P	1	(4)
		c.3280_3281del [‡]	p.(Lys1094Glufs*19)	P	1	Novel
		c.3336dup	p.(Glu1113*)	P	1	(21)
		c.3551C>T	p.(Ala1184Val)	P	1	(22)
		c.3640C>T	p.(Arg1214Trp)	P	1	(23)
		c.4307G>A	p.(Arg1436Gln)	P	1	(24,25)
		c.4406G>T	p.(Gly1469Val)	P	1	(26)
		c.4369G>A [§]	p.(Ala1457Thr)	P	1	(27)
		c.4372C>A	p.(Gln1458Lys)	P	1	Novel
		c.4411G>A [§]	p.(Asp1471Asn)	P	2	(28,29)
		c.4451G>A	p.(Gly1484Glu)	P	1	(30)
		c.4516G>A	p.(Glu1506Lys)	P	14	(10)
		c.4547A>C	p.(Glu1516Ala)	LP	1	Novel
		c.4649T>A [§]	p.(Val1550Asp)	P	1	(27)
		c.4651C>G	p.(Leu1551Val)	P	2	(27)
<i>KCNJ11</i>	NM_000525.3	c.201G>C [¥]	p.(Lys67Asn)	P	2	(27)
		c.539C>T	p.(Thr180Ile)	P	2	Novel
		C>T [¥]	-54 bases proximal of the translation initiation site	P	1	(27)
<i>GLUD1</i>	NM_005271.4	c.965G>A	p.(Arg322His)	P	4	(31)
		c.1493C>T	p.(Ser498Leu)	P	2	(32)
<i>GCK</i>	NM_033508.1	c.193A>G	p.(Thr65Ala)	P	1	Novel
		c.638A>G	p.(Tyr213Cys)	P	1	(33)
<i>SLC16A1</i>	NM_003051.3	c.-391_-390ins25bp	p.?	P	2	(34)
		c.-202G>A	p.?	P	1	(34)
<i>HNF4A</i>	NM_000457.4	c.992G>A	p.(Arg331His)	P	1	(35)

P, pathogenic; LP, likely pathogenic

‡ The variants are compound heterozygous.

§ The variant is compound heterozygous for the founder mutation *ABCC8* /c.560T>A, p.(Val187Asp).

¥ The variants are compound heterozygous.

A (n = 95)

B (n = 65)